
GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.
GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.
Researchers at Brown University may provide a new early diagnostic test for pancreatic cancer.
Encouraging results from mid-trial analysis have prompted an early halt of the clinical trial for palbociclib and plans to apply for approval.
Orteronel combined with prednisone showed significant PFS but not OS in a double-blind, randomized phase 3 trial.
A leading Belgium-based company that offers personalized medicine to cancer patients, OncoDNA, has chosen to partner with N-of-One for interpretation of next-generation sequencing data of tumor samples.
BMS announced in a press release the breakthrough designation received by it's PD-1 inhibitor antibody, nivolumab, for treating Hodgkin's lymphoma.
Stage IV NSCLC patients with metastatic SCC showed significantly improved survival when necitumumab, an EGFR-targeted antibody, was combined with gemcitabine and cisplatin (11.5 months), compared to chemotherapy alone (9.9 months).
Every person covered by Medicare would shell out an additional $3 a month if the government agreed to pay to screen certain current and former smokers for lung cancer, a new study estimates.
NCCN Guidelines Updates
NCCN Guidelines Updates
NCCN Guidelines Updates
NCCN Guidelines Updates
NCCN guidelines Updates
NCCN Guidelines Updates
NCCN Guidelines Updates
NCCN Guidelines Updates
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.